The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...

Modeling Estimates for HCV Related Disease Projections in British Columbia

In support of July 28th being World Hepatitis Day we would like to share with you British Columbia (BC) hepatitis C virus (HCV) disease burden estimates. We have been working with Centre for Disease Analysis to adapt their HCV disease burden model for BC. The model uses a system dynamic framework and projects out the number of infections, decompensated cirrhosis, liver cancers, overall and liver related mortality over time. The model is using input pa